The case for intrauterine stem cell transplantation.
The clinical burden imposed by the collective group of monogenic disorders demands novel therapies that are effective at achieving phenotypic cure early in the disease process before the development of permanent organ damage. This is important for lethal diseases and also for non-perinatally lethal conditions that are characterised by severe disability with little prospect of postnatal cure. Where postnatal treatments are limited to palliative options, intrauterine stem-cell therapies may offer the potential to arrest pathogenesis in the early undamaged fetus. Intrauterine stem-cell transplantation has been attempted for a variety of diseases, but has only been successful in immune deficiency states in the presence of a competitive advantage for donor cells. This disappointing clinical record requires preclinical investigations into strategies that improve donor cell engraftment, including optimising the donor cell source and manipulating the microenvironment to facilitate homing. This chapter aims to outline the current challenges of intrauterine stem-cell therapy.
Experimental Fetal Medicine Group, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. citramattar@nus.edu.sg
Citra N
CN
Mattar
Arijit
A
Biswas
Mahesh
M
Choolani
Jerry K Y
JK
Chan
D005260:Female; D005315:Fetal Diseases / Q000628:therapy; D046128:Fetal Therapies; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D011247:Pregnancy; D033581:Stem Cell Transplantation / Q000379:methods*